QLS-111-FDC, a fixed dose combination of QLS-111 with latanoprost, effectively lowers IOP in a normotensive preclinical mouse modelQLS-111-FDC, a fixed dose combination of QLS-111 with latanoprost, effectively lowers IOP in a normotensive preclinical mouse model